| PDF (6MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-339335
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.33933
Zusammenfassung
Introduction: Kidney fibrosis has shown to be ameliorated through the involvement of cyclic guanosine monophosphate (cGMP) and its dependent protein kinase I (cGKI). Serelaxin, the recombinant form of human relaxin-II, increases cGMP levels and has shown beneficial effects on kidney function in acute heart failure patients. Antifibrotic properties of serelaxin are supposed to be mediated via ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Downloadstatistik